Stem Cell Therapy for Diabetes
Stem Cell Therapy for Diabetes, one of the latest installments of the Stem Cell Biology and Regenerative Medicine series, reviews the three main approaches for generation of sufficient numbers of insulin-producing cells for restoration of an adequate beta
- PDF / 5,386,459 Bytes
- 293 Pages / 439.37 x 666.142 pts Page_size
- 11 Downloads / 248 Views
Series Editor Kursad Turksen, Ph.D. [email protected]
For other titles published in this series, go to http://www.springer.com/series/7896
Shimon Efrat Editor
Stem Cell Therapy for Diabetes
Editor Shimon Efrat Department of Human Molecular Genetics & Biochemistry Tel Aviv University Sackler school of Medicine 69978 Tel Aviv Israel
ISBN 978-1-60761-365-7 e-ISBN 978-1-60761-366-4 DOI 10.1007/978-1-60761-366-4 Library of Congress Control Number: 2009939144 © Humana Press, a part of Springer Science+Business Media, LLC 2010 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper springer.com
Preface
Regenerative medicine is an old human dream, and for the first time in human history its realization is within reach. Diabetes ranks high on the priority list of diseases that can benefit from regenerative medicine interventions. β-cell function is lost in both type 1 and type 2 diabetes. In type 1 β-cell loss results from autoimmune destruction. In type 2 the exact mechanisms of β-cell functional deterioration remain poorly understood, but they likely involve exposure to agents such as islet amyloid polypeptide and free fatty acids, coupled with cell “exhaustion” owing to increased demands for insulin and insufficient β-cell renewal. The incidence of both types of diabetes is on the rise, and the supply of human donor pancreatic tissue for β-cell replacement falls far short of the demand. Stem cells hold a promise for providing an abundant source of cells for cell therapy for diabetes. The generation of human embryonic stem cell lines created expectations for an imminent unlimited supply of all cell types needed in regenerative medicine. A decade later, harnessing the potential of embryonic stem cells remains an attractive prospect, but the initial optimism was replaced by a more realistic appreciation of the difficulties involved in realizing this potential. As a result, the alternative source of tissue stem cells has also become a topic of intense investigation. Ti
Data Loading...
